Aurobindo Pharma Subsidiary's Biosimilar Facility Gets ANVISA Approval

CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has received approval from Brazil's ANVISA for its biosimilar manufacturing facility in Hyderabad. The facility successfully passed a GMP inspection by ANVISA, covering biological API and sterile products, including four biosimilar products and various manufacturing and testing areas. This approval, following existing EMA and WHO certifications, enhances CuraTeQ's ability to supply biosimilar products to Brazil and the wider Latin American market, underscoring the company's commitment to global quality standards.